Brainstorm Cell Therapeutics Inc.
BCLI
$0.642
-$0.0032-0.50%
OTC PK
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -18.60% | 21.76% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -16.70% | -3.14% | |||
| Operating Income | 16.70% | 3.14% | |||
| Income Before Tax | -1.36% | 3.67% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1.36% | 3.67% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1.36% | 3.67% | |||
| EBIT | 16.70% | 3.14% | |||
| EBITDA | 16.96% | 3.16% | |||
| EPS Basic | 25.42% | 13.29% | |||
| Normalized Basic EPS | 25.41% | 13.30% | |||
| EPS Diluted | 25.42% | 13.29% | |||
| Normalized Diluted EPS | 25.41% | 13.30% | |||
| Average Basic Shares Outstanding | 35.93% | 11.11% | |||
| Average Diluted Shares Outstanding | 35.93% | 11.11% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||